ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 575

Distinct Clinical and Immunological Features of Anti-Centromere Antibody Positive Primary Sjögren’s Syndrome: A Single Center Cross-Sectional Cohort Study

Masako Tsukamoto1,2, Katsuya Suzuki1, Noriyuki Seta2 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Sjogren's syndrome and anti-centromere antibodies (ACA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Sjögren's Syndrome Poster I: Translational Research

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-centromere antibody (ACA) positive Sjögren’s syndrome (SS) is considered as a subtype in SS. Recent international collaborative large scale cohort study highlighted several clinical features such as Raynaud’s phenomenon、 sclerodactyly and extra glandular dysfunction (Arthritis Care Res. 2016). Assessment of ACA is potentially valuable for definitive diagnosis of this subtype and medical management in a certain number of patients uncovered by current 2015 ACR/EULAR classification criteria. However, enough information of clinical and immunological features of ACA positive SS has not been accumulated and clinical significance of ACA in SS may not be fully established. The aim of this study is to clarify clinical and immunological features of ACA positive SS.

Methods: All patients with primary SS (pSS) who visited to our Division of Rheumatology at Keio University Hospital in Tokyo between May 1995 and December 2016 were enrolled. Clinical information and immunological tests including immunoglobulin (Ig) and serum autoantibodies were collected and statistically analyzed.

Results: Five hundred and ninety nine patients were clinically classified as pSS (female: 93%, mean age: 55 ± 15). They were divided into 4 groups by serum ACA and anti-SS-A antibody status. Only discrete-speckled pattern in anti-nuclear antibody (ANA) test and/or anti-centromere antibody positive (ACA alone) were detected in 39 patients (6.5%), while only anti-SS-A antibody with no ACA (SS-A alone) were detected in 449 patients (75.0%). Number of patients with both ACA and SS-A (Double positive) was 40 (6.7%), while 67 patients had neither ANA nor SS-A (Seronegative). Then we statistically compared these 4 groups. The proportions of Raynaud’s phenomenon or sclerodactyly were higher in ACA alone and Double positive groups (p<0.01 or p<0.01). The proportion of dryness was no difference among 4 groups. The proportions of increase of serum IgG or IgA were 15% or 7% in ACA alone group, 61% or 20% in SS-A alone group, 50% or 28% in Double positive group and 22% or 4% in Seronegative group (p<0.01 or p<0.01). Existence of anti-SS-A antibody, not ACA associated to high concentration of IgG or IgA, while there was no difference between 4 groups as IgM (p=0.40). Regarding C3, C4 or CH50, there were no differences among 4 groups. Remarkably, the proportion of leukocytopenia in ACA alone group was significantly higher than the others (p=0.02). As compared with pulmonary, cardiac or articular involvements, no differences were found among 4 groups. Importantly the proportion of patients who had facial erythema was significantly lower in ACA positive SS (p<0.01).

Conclusion: Our large-scale study identified distinct characteristics of ACA-positive SS patients different from anti-SS-A/Ro antibody positive or seronegative SS patients in Japanese population.


Disclosure: M. Tsukamoto, None; K. Suzuki, None; N. Seta, None; T. Takeuchi, None.

To cite this abstract in AMA style:

Tsukamoto M, Suzuki K, Seta N, Takeuchi T. Distinct Clinical and Immunological Features of Anti-Centromere Antibody Positive Primary Sjögren’s Syndrome: A Single Center Cross-Sectional Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/distinct-clinical-and-immunological-features-of-anti-centromere-antibody-positive-primary-sjogrens-syndrome-a-single-center-cross-sectional-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-clinical-and-immunological-features-of-anti-centromere-antibody-positive-primary-sjogrens-syndrome-a-single-center-cross-sectional-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology